SPX4,054.10-22.47 -0.55%
DIA343.44-0.97 -0.28%
IXIC11,392.25-90.20 -0.79%

Citigroup Maintains Buy on Pear Therapeutics, Lowers Price Target to $5

Benzinga · 11/16/2022 07:17
Citigroup analyst Neena Bitritto-Garg maintains Pear Therapeutics (NASDAQ:PEAR) with a Buy and lowers the price target from $7 to $5.